The pharmacological properties of the novel selective 5‐HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to investigate the pharmacological properties of the novel, selective 5‐HT 3 receptor antagonist, alosetron, and its effects on transit time in both the normal and perturbed small intestine of the rat. Alosetron concentration‐dependently inhibited radioligand binding in membranes containing rat and human 5‐HT 3 receptors with estimated pKi values of 9.8 (n = 3) and 9.4 (n = 6), respectively. In selectivity studies alosetron had little or no significant affinity for any of the many other receptors and ion channels studied. Alosetron potently antagonized the depolarization produced by 5‐HT in the rat vagus nerve (estimated pK B value of 9.8, n = 25). In anaesthetized rats, i.v. administration of alosetron inhibited 2‐methyl‐5‐HT induced bradycardia (Bezold Jarisch index) at 1 and 3 μg kg–1, with an agonist dose ratio of approximately 3.0 at 1.0 μg kg–1, = 3–5). Alosetron administered via the duodenum also inhibited this reflex, with duration of action that was significantly longer than that seen with ondansetron (120–60 min, respectively, n = 6). Alosetron had no significant effect on normal small intestinal propulsion in the rat, but fully reversed the increase in intestinal propulsion (96%, n = 3) produced by egg albumin challenge. Alosetron is a highly selective 5‐HT 3 antagonist which normalizes perturbed small intestinal propulsion. Previous clinical data in IBS patients together with the transit data provide a good rationale for further studies with alosetron in IBS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome
Ritchie, J. (1973) · Gut · doi:10.1136/gut.14.2.125 · Cited by 832
Cited by
The 5-HT3receptor as a therapeutic target
Thompson, A. J., & Lummis, S. C. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.527 · Cited by 257
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014) · Gut · doi:10.1136/gutjnl-2013-305989 · Cited by 246
Houghton, Foster, & Whorwell (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00762.x · Cited by 132
Min, Y. W., & Rhee, P.-L. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15572580 · Cited by 30
“Likewise, the potency of ondansetron is 3–10 times lower than that of alosetron [Clayton et al. 1999].”
Background
Metadata
- Authors
- CLAYTON, SARGENT, BUTLER, GALE, MAXWELL, HUNT, BARRETT, CAMBRIDGE, BOUNTRA, & HUMPHREY
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 1999-06
- Volume
- 11
- Issue
- 3
- Pages
- 207-217
- ISSN
- 1350-1925 (ISSN-L)
- 1365-2982
- OpenAlex
- W2007269921
- Cited by
- 40
- References
- 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pharmacological properties of the novel selective 5‐HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. https://app.cochat.ai/papers/10.1046/j.1365-2982.1999.00148.x
- The paper
- CLAYTON, SARGENT, BUTLER, GALE, MAXWELL, HUNT, BARRETT, CAMBRIDGE, BOUNTRA, & HUMPHREY. (1999). The pharmacological properties of the novel selective 5‐HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterology & Motility. https://doi.org/10.1046/j.1365-2982.1999.00148.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.